然而，研究人员和制药商却大幅削减了用于对新药剂进行评价和临床试验的资金。
However, researchers and pharmaceutical manufacturers have significantly cut back on funds for the evaluation and clinical testing of new agents.
结果与结论：我国应制订药物经济学评价指南并应用于药品定价、报销目录遴选、临床合理用药、疾病防治策略以及新药研发等卫生决策领域。
RESULTS &CONCLUSION:It's necessary for China to formulate pharmacoeconomic guidelines and use it in drug pricing, drug reimbursement, clinical guidance, diseases prevention and new drug R&D.
心肌损伤生物标志物的检测在心脏疾病临床诊断上被广泛应用，但是在新药的非临床安全评价方面，心肌损伤标志物的应用相对滞后。
The biomarkers of myocardial injury are used widely in clinical diagnosis of heart diseases. However, application of the biomarker in drug preclinical safety evaluation is relatively less.
应用推荐